Axogen, Inc. reported $251M of revenue over the trailing twelve months, +24% on the year before. 10 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $251M (to Q2 2026). Net income: −$34M, trailing twelve months to Q2 2026. Free cash flow: $8.6M, trailing twelve months to Q2 2026. Operating margin: −5.2%, trailing twelve months to Q2 2026.

AXGNAxogen, Inc.

Healthcare

$36.13+110% 1Y

$36.13

$15.5952 weeks$51.57

AXGN as reported

Axogen, Inc. reported $251M of revenue over the trailing twelve months, +24% on the year before. 10 reported series are charted on this page, each one as filed.

$251M

Revenue, trailing twelve months · to Q2 2026 · +24% against the twelve months before

Net income: −$34M
Net income · +619% year on year · trailing twelve months to Q2 2026
Free cash flow: $8.6M
Free cash flow · +74% year on year · trailing twelve months to Q2 2026
Operating margin: −5.2%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for AXGN, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$251M	+24%	Q2 2026
Net income	−$34M	+619%	Q2 2026
EPS	−$0.68	+580%	Q2 2026
Gross margin	75%	n/a	Q2 2026
Operating margin	−5.2%	n/a	Q2 2026
Net margin	−14%	n/a	Q2 2026
ROE	−10.0%	n/a	Q2 2026
ROA	−7.5%	n/a	Q2 2026
ROIC	−3.6%	n/a	Q2 2026
Free cash flow	$8.6M	+74%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.